Beijing Humanwell Junwei Pharmaceutical Technology Development

Beijing Humanwell Junwei Pharmaceutical Technology Development is a specialized research and development subsidiary of Humanwell Healthcare Group, focused on the innovation of analgesic and anesthetic medications. Based in Beijing, the company serves as a key R&D hub for the parent group, particularly in the development of opioid-based therapies and high-end generic drugs. Its most significant achievement is the development of Nalbuphine Hydrochloride, a mixed opioid agonist-antagonist that has become a staple in Chinese pain management. The company integrates drug discovery, clinical research, and technical transfer to bring new therapeutic options to the market. Through its collaboration with other Humanwell subsidiaries, it maintains a strong presence in the central nervous system drug market in China.